Multiple targets have been explored so far for CAR T therapy against GBM, such as IL-13Rα2 [12–14], EGFR/EGFRvIII [15–17], EphA2 [18], HER2 [19, 20], B7-H3 (CD276) [21], GD2 [22], CD70 [23], CD133 [24], CD317 [25] and p32 [26]. This evidence concerns the gene CD276 and glioblastoma.